Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $1.28
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Aug 17, 26 |
Daily · Wilder smoothing
| Piper Sandler |
| maintain |
| Overweight |
| Overweight |
| Nov 22, 24 | Cantor Fitzgerald | maintain | Overweight | Overweight |
| Nov 15, 24 | Cantor Fitzgerald | maintain | Overweight | Overweight |
| Sep 20, 24 | Cantor Fitzgerald | maintain | Overweight | Overweight |
| Aug 29, 24 | Cantor Fitzgerald | maintain | Overweight | Overweight |
| Aug 19, 24 | Benchmark | downgrade | Buy | Hold |
| Aug 9, 24 | Cantor Fitzgerald | maintain | Overweight | Overweight |
| May 3, 24 | Benchmark | maintain | Buy | Buy |
| Feb 29, 24 | Benchmark | upgrade | Hold | Buy |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 43.77 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 34.72 | Oscillator | Neutral |
| Williams %R (14) | -70.83 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.04 (Hist 0.00) | Oscillator | Buy |
| Average Directional Index (14) | 32.27 (+DI 6.9 / -DI 15.8) | Trend | Strong Sell |
| EMA 20 | 1.33 | MA | Strong Sell |
| SMA 20 | 1.34 | MA | Strong Sell |
| EMA 50 | 1.46 | MA | Strong Sell |
| SMA 50 | 1.43 | MA | Strong Sell |
| SMA 200 | 1.83 | MA | Strong Sell |
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure
TTM vs. 5-year historical average (annual ratios)
| Metric | CDXS | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -3.8x | -23.0x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -3.4x | EPS est. -0.38 | In line |
| Price / Book | 3.5x | 5.0x | Discount |
| Price / Sales | 1.8x | 6.5x | Discount |
| EV / EBITDA | -9.0x | -31.1x | Discount |
| Return on equity | -74.4% | — | Weak |
| Gross margin | 83.7% | 78.5% | In line |
| Debt / Equity | 2.20 | 0.62 | Levered |
| Piotroski / Altman Z | 3/9 | Z -6.03 | Distress |
Discounted cash flow model
Stock news · updated daily
REDWOOD CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Codexis , Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced an agreement with a pioneering siRNA drug innovator to explore stereo-defined fragment synthesis using its ECO Synthesis® Manufacturing Platform.
Revvity (NYSE: RVTY - Get Free Report) and Codexis (NASDAQ: CDXS - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk. Institutional and Insider Ownership 86.7% of Revvity shares are held
Mettler-Toledo International (NYSE: MTD - Get Free Report) and Codexis (NASDAQ: CDXS - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, profitability and analyst recommendations. Volatility and Risk Mettler-Toledo International has a beta of
BlackRock Inc. bought a new stake in shares of Codexis, Inc. (NASDAQ: CDXS) during the undefined quarter, according to its most recent Form 13F filing with the SEC. The fund bought 7,284,352 shares of the biotechnology company's stock, valued at approximately $16,463,000. BlackRock Inc. owned 8.01% of Codexis as of its most recent
REDWOOD CITY, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced the Company will attend the Cantor Global Healthcare Conference 2026, being held September 9-11, 2026, in New York, New York.
Codexis (CDXS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Codexis, Inc. (CDXS) Q2 2026 Earnings Call Transcript
Codexis (CDXS) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.16 per share a year ago.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 11, 2026 | -0.14 | -0.13 | Beat 8.2% | $14.91M |
| May 7, 2026 | -0.11 | -0.10 | Beat 9.1% | $15.25M |
| Mar 11, 2026 | 0.01 | 0.11 | Beat 1000.0% | $38.91M |
| Nov 6, 2025 | -0.15 | -0.22 | Miss -46.7% | $8.60M |
| Aug 13, 2025 | -0.17 | -0.16 | Beat 5.9% | $15.33M |
| May 14, 2025 | -0.20 | -0.25 | Miss -25.0% | $7.54M |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Oct 14, 2026 | 2026-10-14 17:19:51 | View |
| 4 | Oct 14, 2026 | 2026-10-14 17:17:11 | View |
| SC 13G/A | Aug 13, 2026 | 2026-08-13 14:08:59 | View |
| 10-Q | Aug 11, 2026 | 2026-08-11 16:21:14 | View |
| 8-K | Aug 11, 2026 | 2026-08-11 16:11:09 | View |
| SC 13G | Jul 29, 2026 | 2026-07-29 15:55:06 | View |
| 8-K | Jul 27, 2026 | 2026-07-27 16:02:34 | View |
| 424B5 | Jul 24, 2026 | 2026-07-24 16:01:56 | View |
| 424B5 | Jul 23, 2026 | 2026-07-23 16:41:40 | View |
| 8-K | Jul 23, 2026 | 2026-07-23 16:22:28 | View |
Proxy statement (DEF 14A) disclosures
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 12, 26 | Erbez Georgia | officer: See Remarks | S-Sale | 6,335 @ $1.36 | $8.62K |
| Oct 12, 26 | Moore Alison | director, officer: President and CEO | S-Sale | 6,335 @ $1.36 | $8.62K |
| Jun 17, 26 | Parker H Stewart | director | A-Award | 66,350 @ $2.48 | $164.5K |
| Jun 17, 26 | Collins Cynthia | director | A-Award | 66,350 @ $2.48 | $164.5K |
| Jun 17, 26 | Richards Christos | director | A-Award | 66,350 @ $2.48 | $164.5K |
| Jun 17, 26 | Smith David V | director | A-Award | 66,350 @ $2.48 | $164.5K |
| Jun 17, 26 | Singhvi Rahul | director | A-Award | 66,350 @ $2.48 | $164.5K |
| Jun 17, 26 | Martinborough Esther | director | A-Award | 66,350 @ $2.48 | $164.5K |